HRP20170845T1 - Hiperbulirajući sojevi bakterije shigella - Google Patents
Hiperbulirajući sojevi bakterije shigella Download PDFInfo
- Publication number
- HRP20170845T1 HRP20170845T1 HRP20170845TT HRP20170845T HRP20170845T1 HR P20170845 T1 HRP20170845 T1 HR P20170845T1 HR P20170845T T HRP20170845T T HR P20170845TT HR P20170845 T HRP20170845 T HR P20170845T HR P20170845 T1 HRP20170845 T1 HR P20170845T1
- Authority
- HR
- Croatia
- Prior art keywords
- bacterium
- bacteria
- shigella
- accordance
- preparation
- Prior art date
Links
- 241000607768 Shigella Species 0.000 title claims 12
- 241000894006 Bacteria Species 0.000 claims 25
- 238000002360 preparation method Methods 0.000 claims 11
- 238000000034 method Methods 0.000 claims 9
- 208000002352 blister Diseases 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 239000002609 medium Substances 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 239000001963 growth medium Substances 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 241000350158 Prioria balsamifera Species 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 208000004429 Bacillary Dysentery Diseases 0.000 claims 1
- 241000197194 Bulla Species 0.000 claims 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010040550 Shigella infections Diseases 0.000 claims 1
- RHTNTTODYGNRSP-UHFFFAOYSA-N Tolazoline hydrochloride Chemical compound Cl.C=1C=CC=CC=1CC1=NCCN1 RHTNTTODYGNRSP-UHFFFAOYSA-N 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000706 filtrate Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 201000005113 shigellosis Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 101150081449 stxA gene Proteins 0.000 claims 1
- 101150017169 stxB gene Proteins 0.000 claims 1
- 101150061964 tolA gene Proteins 0.000 claims 1
- 101150014665 tolB gene Proteins 0.000 claims 1
- 101150026694 tolQ gene Proteins 0.000 claims 1
- 101150088820 tolR gene Proteins 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (22)
1. Hiperbulirajuća bakterija Shigella, naznačena time što eksprimira najviše 4 od proteina TolA, TolB, TolQ, TolR i Pal, te što ne eksprimira nativni Shigella lipopolisaharid.
2. Bakterija u skladu s patentnim zahtjevom 1, naznačena time što bakterija eksprimira 4 od proteina, no ne i TolR.
3. Bakterija u skladu s patentnim zahtjevom 1, naznačena time što ne eksprimira protein TolR.
4. Bakterija u skladu s patentnim zahtjevom 3, naznačena time što je soj ΔtolR bakterije Shigella.
5. Bakterija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što bakterija ne eksprimira nativni Shigella antigen O.
6. Bakterija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je struktura nativnog lipida A poremećena.
7. Bakterija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je soj ΔtolRΔmsbB ili ΔtolRΔhtrB.
8. Bakterija u skladu s patentnim zahtjevom 4, naznačena time što je soj soj ΔtodRΔgalU.
9. Bakterija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je gen stxA i/ili stxB inaktiviran.
10. Postupak priprave bula iz bakterije Shigella, naznačen time što obuhvaća korak izdvajanja bula iz medija za uzgoj koji sadrži bakteriju u skladu s bilo kojim od patentnih zahtjeva 1 do 9, uzgajanu u uvjetima koji omogućuju otpuštanje bula u medij od strane bakterija; izborno kada su bakterije uzgajane u uvjetima s ograničenom količinom željeza.
11. Postupak priprave hiperbulirajuće bakterije Shigella, naznačen time što obuhvaća korak modificiranja jednog ili više gena koji kodiraju jednu ili više komponentata sustava Tol-Pal iz polazne bakterije, tako da modificiranje uzrokuje da bakterija, prilikom uzgoja u mediju za uzgoj, otpušta veće količine bula vanjske membrane u medij nego polazna bakterija, što modificiranje uključuje mutiranje jednog ili više gena tolA, tolB, tolQ, tolR i/ili pal iz polazne bakterije, te što bakterija Shigella ne eksprimira nativni Shigella lipopolisaharid.
12. Vezikula, naznačena time što se izolira ili se može dobiti (a) iz bakterije u skladu s bilo kojim od patentnih zahtjeva 1 do 9 (b) iz bakterije koja se može dobiti postupkom u skladu s patentnim zahtjevom 11, ili (c) postupkom u skladu s patentnim zahtjevom 10.
13. Pripravak, naznačen time što sadrži bule koje se, tijekom uzgoja bakterije u skladu s bilo kojim od patentnih zahtjeva 1 do 9 ili koji se može dobiti postupkom u skladu s patentnim zahtjevom 11, otpušta u medij za uzgoj; izborno kada pripravak ne sadrži žive i/ili cijele bakterije.
14. Pripravak u skladu s patentnim zahtjevom 13, naznačen time što su bule prisutne u filtratu koji se može dobiti filtriranjem kroz 0,22 µm filtar medija za uzgoj u kojem je uzgajana bakterija u skladu s bilo kojim od patentnih zahtjeva 1 do 9 ili koji se može dobiti postupkom u skladu s patentnim zahtjevom 11.
15. Mediji za uzgoj koji sadrže bakterije u skladu s patentnim zahtjevima 1 do 9, ili koje se može dobiti postupkom u skladu s patentnim zahtjevom 11, naznačen time što su bakterije uzgajane u uvjetima koji omogućuju otpuštanje bula u medij od strane bakterija.
16. Vezikula u skladu s patentnim zahtjevom 12 ili pripravak u skladu s patentnim zahtjevom 13 ili 14, naznačeni time što su namijenjeni upotrebi u postupku poticanja stvaranja protutijela kao odgovora kod sisavca, koji obuhvaća primjenu bule ili pripravka na sisavcu.
17. Vezikula u skladu s patentnim zahtjevom 12 ili pripravak u skladu s patentnim zahtjevom 13 ili 14, naznačeni time što su namijenjeni upotrebi u proizvodnji medikamenta za sprečavanje zaraze uzrokovane bakterijom Shigella kod sisavca.
18. Vezikula u skladu s patentnim zahtjevom 12 ili pripravak u skladu s patentnim zahtjevom 13 ili 14, naznačeni time što su namijenjeni upotrebi u postupku zaštite sisavca od zaraze i/ili bolesti uzrokovane bakterijom Shigella.
19. Vezikula ili pripravak u skladu s patentnim zahtjevom 17 ili 18, naznačeni time što su namijenjeni upotrebi u skladu s patentnim zahtjevima 17 ili 18, gdje je zaraza i/ili bolest uzrokovana bakterijom Shigella šigeloza, Reiterov sindrom i/ili hemolitički uremični sindrom.
20. Vezikula ili pripravak u skladu s patentnim zahtjevima 16 do 19, naznačeni time što su namijenjeni upotrebi u skladu s patentnim zahtjevima 17 do 19, gdje je sisavac čovjek.
21. Vezikula u skladu s patentnim zahtjevom 12 ili pripravak u skladu s patentnim zahtjevom 13 ili 14, naznačeni time što su namijenjeni upotrebi kao medikament.
22. Vezikula ili pripravak u skladu s patentnim zahtjevima 17 ili 21, naznačeni time što su namijenjeni upotrebi u skladu s patentnim zahtjevima 17 ili 21, gdje je medikament cjepivo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0917002.8A GB0917002D0 (en) | 2009-09-28 | 2009-09-28 | Improved shigella blebs |
| EP10768559.6A EP2483389B1 (en) | 2009-09-28 | 2010-09-28 | Hyperblebbing shigella strains |
| PCT/IB2010/002582 WO2011036564A2 (en) | 2009-09-28 | 2010-09-28 | Hyperblebbing shigella strains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170845T1 true HRP20170845T1 (hr) | 2017-08-11 |
Family
ID=41350492
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170845TT HRP20170845T1 (hr) | 2009-09-28 | 2017-06-02 | Hiperbulirajući sojevi bakterije shigella |
| HRP20210243TT HRP20210243T1 (hr) | 2009-09-28 | 2021-02-11 | Hiperbulirajući sojevi bakterije shigella |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210243TT HRP20210243T1 (hr) | 2009-09-28 | 2021-02-11 | Hiperbulirajući sojevi bakterije shigella |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20130052227A1 (hr) |
| EP (2) | EP3279313B1 (hr) |
| JP (3) | JP2013505716A (hr) |
| KR (1) | KR101786025B1 (hr) |
| CN (2) | CN102906245B (hr) |
| AU (1) | AU2010299577B2 (hr) |
| BR (1) | BR112012006912A8 (hr) |
| CA (1) | CA2775642C (hr) |
| CY (2) | CY1118970T1 (hr) |
| DK (2) | DK3279313T3 (hr) |
| ES (2) | ES2846901T3 (hr) |
| GB (1) | GB0917002D0 (hr) |
| HR (2) | HRP20170845T1 (hr) |
| HU (1) | HUE053188T2 (hr) |
| LT (2) | LT3279313T (hr) |
| NZ (1) | NZ599598A (hr) |
| PL (2) | PL2483389T3 (hr) |
| PT (2) | PT3279313T (hr) |
| SI (2) | SI3279313T1 (hr) |
| WO (1) | WO2011036564A2 (hr) |
| ZA (1) | ZA201202934B (hr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8647642B2 (en) | 2008-09-18 | 2014-02-11 | Aviex Technologies, Llc | Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment |
| GB201017519D0 (en) | 2010-10-15 | 2010-12-01 | Novartis Vaccines Inst For Global Health S R L | Vaccines |
| WO2014076714A2 (en) * | 2012-11-19 | 2014-05-22 | Indian Council Of Medical Research | Novel immunogenic antigens of shigella |
| US9636390B2 (en) | 2012-11-19 | 2017-05-02 | Indian Council Of Medical Research | Immunogenic antigens of shigella |
| US10376571B2 (en) * | 2013-03-15 | 2019-08-13 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to enteric pathogens |
| EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
| CN104974946B (zh) * | 2014-04-08 | 2019-01-11 | 中国科学院天津工业生物技术研究所 | 耐高渗透压的重组大肠杆菌及其应用 |
| CL2014001126A1 (es) * | 2014-04-29 | 2014-08-29 | Univ Chile | Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec. |
| WO2016202872A1 (en) | 2015-06-16 | 2016-12-22 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| CN105647892A (zh) * | 2016-03-04 | 2016-06-08 | 江南大学 | 一种D-丙氨酰-D-丙氨酸羧肽酶dacA基因及应用 |
| CN105647893A (zh) * | 2016-03-04 | 2016-06-08 | 江南大学 | 一种D-丙氨酰-D-丙氨酸羧肽酶dacD基因及应用 |
| KR20230070521A (ko) | 2016-05-03 | 2023-05-23 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법 |
| US20170360881A1 (en) * | 2016-06-17 | 2017-12-21 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| EP3263695A1 (en) | 2016-06-29 | 2018-01-03 | GlaxoSmithKline Biologicals SA | Immunogenic compositions |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| WO2019163785A1 (ja) * | 2018-02-20 | 2019-08-29 | 株式会社山田養蜂場本社 | 膜小胞組成物の製造方法 |
| EP3827085A1 (de) * | 2018-07-24 | 2021-06-02 | Wacker Chemie AG | Neue bakterielle lpp-mutante und deren verwendung zur sekretorischen herstellung von rekombinanten proteinen |
| CN111363018B (zh) * | 2020-03-26 | 2021-10-01 | 廊坊梅花生物技术开发有限公司 | 重组菌株及其在l-色氨酸制备中的应用 |
| WO2022133289A2 (en) * | 2020-12-18 | 2022-06-23 | Codexis, Inc. | Engineered uridine phosphorylase variant enzymes |
| GB202112149D0 (en) | 2021-08-24 | 2021-10-06 | Glaxosmithkline Biologicals Sa | Shigellla vaccine |
| CN113897324B (zh) * | 2021-10-13 | 2023-07-28 | 云南师范大学 | 一种用作抗锰剂的JcVIPP1重组大肠杆菌及其构建方法 |
| GB202118913D0 (en) | 2021-12-23 | 2022-02-09 | Glaxosmithkline Biologicals Sa | Method for preparing outer membrane vesicles |
| CN116855471B (zh) * | 2023-09-04 | 2023-11-28 | 江苏申基生物科技有限公司 | 一种嘌呤核苷磷酸化酶突变体及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| AU627226B2 (en) | 1988-08-25 | 1992-08-20 | Liposome Company, Inc., The | Influenza vaccine and novel adjuvants |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| PL170980B1 (pl) | 1992-06-25 | 1997-02-28 | Smithkline Beecham Biolog | Szczepionka PL PL PL PL PL PL PL |
| ES2162139T5 (es) | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
| AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5679564A (en) | 1994-10-05 | 1997-10-21 | Antex Biologics, Inc. | Methods for producing enhanced antigenic campylobacter bacteria and vaccines |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| US6887483B2 (en) * | 1995-12-01 | 2005-05-03 | University Of Iowa Research Foundation | Non-toxic mutants of pathogenic gram-negative bacteria |
| DK1005368T3 (da) | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer |
| US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| ES2298316T3 (es) | 1997-09-05 | 2008-05-16 | Glaxosmithkline Biologicals S.A. | Emulsiones de aceite en agua que contienen saponinas. |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| AU759391B2 (en) | 1998-02-12 | 2003-04-10 | Wyeth Holdings Corporation | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| WO2001025254A2 (en) * | 1999-10-04 | 2001-04-12 | University Of Maryland Biotechnology Institute | Novel adjuvant comprising a lipopolysaccharide antagonist |
| US20010044416A1 (en) | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
| EP1322656B1 (en) | 2000-09-26 | 2008-01-16 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| GB0103171D0 (en) * | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| KR101239242B1 (ko) | 2002-08-02 | 2013-03-11 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 항원 조합물을 포함하는 나이세리아 백신 조성물 |
| JP4676426B2 (ja) | 2003-03-24 | 2011-04-27 | インターツェル・アクチェンゲゼルシャフト | 改良型ワクチン |
| NZ550152A (en) | 2004-04-05 | 2009-04-30 | Pfizer Prod Inc | Microfluidized oil-in-water emulsions and vaccine compositions |
| AU2012207041A1 (en) | 2005-02-18 | 2012-08-16 | J. Craig Venter Institute, Inc. | Proteins and nucleic acids from meningitis/sepsis-associated Escherichia Coli |
| NZ560929A (en) | 2005-02-18 | 2009-12-24 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic escherichia coli |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
-
2009
- 2009-09-28 GB GBGB0917002.8A patent/GB0917002D0/en not_active Ceased
-
2010
- 2010-09-28 LT LTEP17168855.9T patent/LT3279313T/lt unknown
- 2010-09-28 LT LTEP10768559.6T patent/LT2483389T/lt unknown
- 2010-09-28 AU AU2010299577A patent/AU2010299577B2/en active Active
- 2010-09-28 CN CN201080052643.0A patent/CN102906245B/zh active Active
- 2010-09-28 ES ES17168855T patent/ES2846901T3/es active Active
- 2010-09-28 DK DK17168855.9T patent/DK3279313T3/da active
- 2010-09-28 PL PL10768559T patent/PL2483389T3/pl unknown
- 2010-09-28 PT PT171688559T patent/PT3279313T/pt unknown
- 2010-09-28 US US13/498,723 patent/US20130052227A1/en not_active Abandoned
- 2010-09-28 HU HUE17168855A patent/HUE053188T2/hu unknown
- 2010-09-28 PL PL17168855T patent/PL3279313T3/pl unknown
- 2010-09-28 SI SI201032053T patent/SI3279313T1/sl unknown
- 2010-09-28 EP EP17168855.9A patent/EP3279313B1/en active Active
- 2010-09-28 SI SI201031507T patent/SI2483389T1/sl unknown
- 2010-09-28 ES ES10768559.6T patent/ES2632747T3/es active Active
- 2010-09-28 NZ NZ599598A patent/NZ599598A/xx not_active IP Right Cessation
- 2010-09-28 DK DK10768559.6T patent/DK2483389T3/en active
- 2010-09-28 PT PT107685596T patent/PT2483389T/pt unknown
- 2010-09-28 CA CA2775642A patent/CA2775642C/en active Active
- 2010-09-28 KR KR1020127011091A patent/KR101786025B1/ko active IP Right Grant
- 2010-09-28 BR BR112012006912A patent/BR112012006912A8/pt not_active Application Discontinuation
- 2010-09-28 WO PCT/IB2010/002582 patent/WO2011036564A2/en active Application Filing
- 2010-09-28 CN CN201710653787.5A patent/CN107475168A/zh active Pending
- 2010-09-28 JP JP2012530359A patent/JP2013505716A/ja active Pending
- 2010-09-28 EP EP10768559.6A patent/EP2483389B1/en active Active
-
2012
- 2012-04-20 ZA ZA2012/02934A patent/ZA201202934B/en unknown
-
2016
- 2016-03-15 JP JP2016050789A patent/JP2016105736A/ja active Pending
- 2016-04-08 US US15/094,077 patent/US11339367B2/en active Active
-
2017
- 2017-06-02 HR HRP20170845TT patent/HRP20170845T1/hr unknown
- 2017-06-16 CY CY20171100637T patent/CY1118970T1/el unknown
-
2019
- 2019-02-08 JP JP2019021756A patent/JP7023248B2/ja active Active
-
2021
- 2021-02-04 CY CY20211100093T patent/CY1123774T1/el unknown
- 2021-02-11 HR HRP20210243TT patent/HRP20210243T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170845T1 (hr) | Hiperbulirajući sojevi bakterije shigella | |
| WO2019205753A1 (en) | A composite multi-epitope expression cassette, a recombinant virus composed thereof and application thereof | |
| HU229101B1 (en) | Dna transfection system for the generation of infectious influenza virus | |
| CN105555306A (zh) | 免疫原性中东呼吸综合征冠状病毒(MERS-CoV)组合物和方法 | |
| RU2606022C2 (ru) | Способ получения капсульного полисахарида с пневмококковым серотипом | |
| CN104293741A (zh) | 一种呼吸道合胞病毒病毒样颗粒疫苗及其制备方法和应用 | |
| Vasilakis et al. | Niakha virus: a novel member of the family Rhabdoviridae isolated from phlebotomine sandflies in Senegal | |
| JP2011500592A5 (hr) | ||
| CN108728490A (zh) | 一种基于杆状病毒载体的鲤疱疹病毒ii型dna疫苗及其构建方法与应用 | |
| WO2014185439A1 (ja) | コイ科ヘルペスウイルス－２（Ｃｙｐｒｉｎｉｄ ｈｅｒｐｅｓｖｉｒｕｓ－２：ＣｙＨＶ－２）感染症用ワクチンおよびその製造方法、ならびにＣｙＨＶ－２ウイルス製造方法 | |
| CN110004178A (zh) | 一种牛病毒性腹泻病毒样颗粒的制备的制备方法 | |
| JP2010538619A5 (hr) | ||
| Kembou-Ringert et al. | Tilapia lake virus vaccine development: a review on the recent advances | |
| JP2006304628A (ja) | 真珠の養殖方法 | |
| CA3090088C (en) | Polyvalent vaccine against salmonid alphavirus infections | |
| EP2454374B1 (en) | Oral vaccines produced and administered using edible micro-organism | |
| CA2570050A1 (en) | Heart and skeletal muscle inflammation (hsmi) virus | |
| O’Connell et al. | Humanized mice for live-attenuated vaccine research: From unmet potential to new promises | |
| CN104725503A (zh) | 一种红鳍东方鲀神经坏死病毒衣壳蛋白卵黄抗体及其应用 | |
| CA2634144C (en) | Novel fish pathogen | |
| CN104017060B (zh) | 用于制备卵黄抗体的大肠杆菌菌毛抗原的提取方法和制备卵黄抗体的方法 | |
| JP2016036285A (ja) | 乳酸菌の製造方法 | |
| RU2493872C1 (ru) | Способ очистки вируса гриппа | |
| CN102363751A (zh) | 登革病毒样颗粒及其制备方法与应用 | |
| CN106350475A (zh) | 一种新型火鸡疱疹病毒的细菌人工染色体、构建方法与应用 |